Pacific Biosciences of California, Inc. Investment Income, Net
Pacific Biosciences of California, Inc. (PACB) reported Investment Income, Net of $2.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-06
- Pacific Biosciences of California, Inc. investment income, net for the quarter ending 2026-06-30 was $2.20M, a 35.29% decline year-over-year.
- Pacific Biosciences of California, Inc. investment income, net for the quarter ending 2026-03-31 was $2.50M, a 35.90% decline year-over-year.
- Pacific Biosciences of California, Inc. investment income, net for the quarter ending 2025-12-31 was $2.70M, a 47.06% decline year-over-year.
- Pacific Biosciences of California, Inc. investment income, net for the quarter ending 2025-09-30 was $3.10M, a 48.33% decline year-over-year.
- Pacific Biosciences of California, Inc. investment income, net for fiscal 2025 was $13.10M, a 47.39% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. investment income, net for fiscal 2024 was $24.90M, a 24.09% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. investment income, net for fiscal 2023 was $32.80M, a 256.52% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. investment income, net for fiscal 2022 was $9.20M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.20M 10-Q · filed 2026-08-06 | $4.70M 10-Q · filed 2026-08-06 | $7.40M derived: sum of 3 quarters · filed 2026-08-06 | $10.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-08 | $5.20M derived: sum of 2 quarters · filed 2026-05-08 | $8.30M derived: sum of 3 quarters · filed 2026-05-08 | $11.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.80M derived: sum of 2 quarters · filed 2026-02-25 | $9.20M derived: sum of 3 quarters · filed 2026-08-06 | $13.10M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.10M 10-Q · filed 2025-11-06 | $6.50M derived: sum of 2 quarters · filed 2026-08-06 | $10.40M 10-Q · filed 2025-11-06 | $15.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.40M 10-Q · filed 2026-08-06 | $7.30M 10-Q · filed 2026-08-06 | $12.40M derived: sum of 3 quarters · filed 2026-08-06 | $18.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.90M 10-Q · filed 2026-05-08 | $9.00M derived: sum of 2 quarters · filed 2026-05-08 | $15.00M derived: sum of 3 quarters · filed 2026-05-08 | $21.50M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.10M derived: sum of 2 quarters · filed 2026-02-25 | $17.60M derived: sum of 3 quarters · filed 2026-02-25 | $24.90M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.00M 10-Q · filed 2025-11-06 | $12.50M derived: sum of 2 quarters · filed 2025-11-06 | $19.80M 10-Q · filed 2025-11-06 | $27.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.50M 10-Q · filed 2025-08-07 | $13.80M 10-Q · filed 2025-08-07 | $21.50M derived: sum of 3 quarters · filed 2025-08-07 | $30.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $7.20M 10-Q · filed 2025-05-12 | $15.00M derived: sum of 2 quarters · filed 2025-05-12 | $24.20M derived: sum of 3 quarters · filed 2025-05-12 | $33.20M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $17.00M derived: sum of 2 quarters · filed 2025-03-17 | $26.00M derived: sum of 3 quarters · filed 2025-03-17 | $32.80M 10-K · filed 2025-03-17 |
| 2023-09-30 | $9.20M 10-Q · filed 2024-11-12 | $18.20M derived: sum of 2 quarters · filed 2024-11-12 | $25.00M 10-Q · filed 2024-11-12 | $29.90M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $9.00M 10-Q · filed 2024-08-09 | $15.80M 10-Q · filed 2024-08-09 | $20.70M derived: sum of 3 quarters · filed 2024-08-09 | $23.50M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $6.80M 10-Q · filed 2024-05-09 | $11.70M derived: sum of 2 quarters · filed 2024-05-09 | $14.50M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $7.70M derived: sum of 2 quarters · filed 2024-02-28 | $9.20M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $2.80M 10-Q · filed 2023-11-03 | $4.30M 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |